By Michael Dabaie

 

Exelixis Inc. said it is in a clinical trial collaboration and supply agreement with Bristol Myers Squibb Co. for a Phase 1b trial evaluating XL092 in combination with immuno-oncology therapies in advanced solid tumors.

The objective of the study is to evaluate the safety, tolerability and efficacy of Exelixis' XL092, in combination with: nivolumab, or Opdivo; nivolumab and ipilimumab, or Yervoy; and nivolumab and bempegaldesleukin.

Exelixis said it is sponsoring the trial and Bristol Myers Squibb will provide nivolumab, ipilimumab and bempegaldesleukin for use in the trial.

Nektar Therapeutics will supply bempegaldesleukin to Bristol Myers Squibb through their existing global development and commercialization collaboration.

The STELLAR-002 study will begin with a dose-escalation phase to determine the recommend dose for each of the combination therapies.

Expansion cohorts to include patients with advanced kidney, prostate and bladder cancers, Exelixis said.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

June 14, 2021 09:01 ET (13:01 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Jun 2021 to Jul 2021 Click Here for more Nektar Therapeutics Charts.
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Jul 2020 to Jul 2021 Click Here for more Nektar Therapeutics Charts.